Headlines about ZIOPHARM Oncology (NASDAQ:ZIOP) have been trending somewhat positive on Friday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 48.4845366547042 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia (finance.yahoo.com)
- 2 Stocks to Track: Endeavour Silver Corp. (NYSE:EXK), ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) – The Oracle Examiner (oracleexaminer.com)
- Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference … – GlobeNewswire (press release) (globenewswire.com)
- Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1 (finance.yahoo.com)
- Today Analysts Focus on: Caesars Entertainment Corporation, (NASDAQ: CZR), ZIOPHARM Oncology, Inc., (NASDAQ … – TNN (tradingnewsnow.com)
Shares of ZIOPHARM Oncology (ZIOP) traded up $0.06 on Friday, hitting $3.94. 494,605 shares of the company’s stock were exchanged, compared to its average volume of 2,028,630. The firm has a market cap of $559.33, a price-to-earnings ratio of -7.57 and a beta of 1.42. ZIOPHARM Oncology has a 52 week low of $3.33 and a 52 week high of $7.88.
A number of brokerages recently issued reports on ZIOP. Zacks Investment Research restated a “hold” rating on shares of ZIOPHARM Oncology in a research report on Saturday, January 13th. BidaskClub lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. ZIOPHARM Oncology currently has a consensus rating of “Hold” and a consensus target price of $12.67.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/16/ziopharm-oncology-ziop-receives-daily-media-impact-rating-of-0-04.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.